Sibley Christopher D, Parkins Michael D, Rabin Harvey R, Surette Michael G
Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada.
Curr Opin Investig Drugs. 2009 Aug;10(8):787-94.
A comprehensive analysis of the airway microbiome in cystic fibrosis (CF) has revealed that the airways are a reservoir of previously unrecognized but clinically relevant organisms. Traditionally, antibiotic intervention in patients with CF presenting with acute bronchopulmonary exacerbations has been directed at a limited number of bacterial pathogens. In patients chronically colonized by conventional pathogens that demonstrate no bacteriological response to standard therapy, other antibiotics may have clinical efficacy. Using a case-based example, this review argues that pathogen-directed treatment based on inclusive quantitative microbiological protocols can result in improved patient outcomes. Furthermore, future therapeutic approaches that may rely on a polymicrobial perspective of the airways in CF are discussed.
对囊性纤维化(CF)气道微生物群的全面分析表明,气道是以前未被认识但具有临床相关性的生物体的储存库。传统上,对出现急性支气管肺加重的CF患者进行抗生素干预时,针对的是有限数量的细菌病原体。对于长期被传统病原体定植且对标准治疗无细菌学反应的患者,其他抗生素可能具有临床疗效。通过一个基于病例的例子,本综述认为基于全面定量微生物学方案的病原体导向治疗可改善患者预后。此外,还讨论了未来可能依赖于CF气道微生物群视角的治疗方法。